Clinical Trial Search

Primary: Percentage of Participants With GVHD/Relapse or Progression-free Survival (GRFS) — 35.5; 27.2; 44.1 percentage of participants

Primary: Number of Complete Response (CR) at Day 28 of Therapy — 12; 27; 25; 16 participants

Primary: GVHD-free Survival — 60; 69; 59; 47 participants

Primary: Proportion of Participants With Treatment Success — 33; 35; 33; 37 Participants — p=0.63

Primary: Mean Cumulative Prednisone Dose (mg/kg) Over 42 Days From the Start of Treatment — 22.2; 27.1; 38.4; 41.3 milligrams per kilogram — p=0.08

Primary: Incidence of Acute GVHD — 45.0 percentage of participants

Primary: Number of Participants With Complete Response (CR) — 34 Participants

Primary: GVHD-free Relapse-Free Survival — 19.3 percentage of subjects

Primary: Phase I: Maximum Tolerated Dose (MTD) in Milligrams — 5 MTD of oral LBH589 in milligrams

Primary: Number of Participants Experiencing Treatment Success — 8 Participants

Primary: Number of Participants With the Ability to Successfully Taper Prednisone to a Dose Lower Dose. — 14 Participants

Primary: Incidence of Clinician-diagnosed Chronic GVHD at One and Two Years — 38; 48 percentage of participants

Primary: Incidence of Adverse Events — 19; 18 participants

Primary: The Maximum Tolerated Dose and Toxicity Profile of an 8 Week Course of IL-2 in Patients With cGVHD and an Inadequate Response to Steroids. — 1 million IU/m2/day

Primary: Maximum Tolerated Dose of Ofatumumab — 1000 mg

Primary: Number of Participants With an Overall Response at Week 28 — 20; 14 Participants — p=0.373

Primary: Day 56 Treatment Success — 57; 72; 43; 47 percentage of participants

Primary: Number (Percentage) of Patients at Each Dosing Cohort Who Experience no Toxicity and in Whom Graft Versus Host Disease (GVHD) is Stable or Improved — 6; 2; 2 Participants

Primary: Maximum-tolerated Dose of MLN9708. — 4 millligram

Primary: Rate of Complete Response of cGVHD to Treatment. — 84 percentage of patients — p=<0.5

Primary: Overall Response Rate After a 15 Week Course of Bortezomib Plus Prednisone in Patients With cGVHD — 2; 14; 1; 2 participants

Primary: Percentage of Participants With Evidence of Acute Graft Versus Host Disease (aGVHD), Post Transplant — 43; 89 percentage of participants

Primary: Feasibility of Enrolling Patients — 21 Participants

Primary: Number of Participants With Complete or Partial Remission of Chronic Graft Versus Host Disease After a First Line Treatment With Arsenic Trioxide — 15 Participants

Primary: Grades II-IV aGVHD — 11 Participants

Primary: The Number of Patients With GVHD/Relapse-free (GRFS) Survival — 25 Participants

Primary: Clinical Response of Patients With Refractory Chronic GVHD Based on the Working Group Report 2006. — 100; 78; 80 percentage of participants

Primary: Safety and Tolerability of Belimumab as Prophylaxis of Chronic GvHD in Subjects Following alloHCT as Measured by Number of Participants Who Experience Each Adverse Event…

Primary: The Maximum Tolerated Dose (MTD) of a Four-week Course of Alemtuxumab in Chronic GVHD for Patients With an Incomplete Response to Steroids — 53 mg

Primary: Number of Patients Absence of Grade II-IV aGVHD or Chronic GVHD Diagnostic Features — 13; 5 Participants